<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RINGERS- sodium chloride, calcium chloride and potassium chloride injection </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>Ringer’s Injection, USP<br>in VIAFLEX Plastic Container</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_165a1555-32dd-40d6-aba8-83e8e3691171"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ringer’s Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents. The pH may have been adjusted with sodium hydroxide. Composition, osmolarity, pH and ionic concentration are shown in Table 1.</p>
<a name="_RefIDA70F584D7C804C6BA0A5EDE636822B42"></a><table width="100%">
<caption><span>Table 1. </span></caption>
<col width="10%">
<col width="6%">
<col width="9%">
<col width="12%">
<col width="10%">
<col width="12%">
<col width="5%">
<col width="8%">
<col width="10%">
<col width="9%">
<col width="9%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Toprule" colspan="11"></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First">   </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> Size (mL) </p></td>
<td class="Botrule Lrule" align="center" colspan="3"><p class="First"> Composition (g/L) </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> Osmolarity (mOsmol/L) (calc) </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First">pH</p></td>
<td class="Botrule Lrule" align="center" colspan="4"><p class="First"> Ionic Concentration (mEq/L) </p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"> Sodium Chloride, USP (NaCl) </p></td>
<td class="Botrule Lrule" align="center"><p class="First"> Calcium Chloride, USP(CaCl<span class="Sub">2</span>-2H<span class="Sub">2</span>O) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">Potassium Chloride, USP (KCl)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Sodium</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Potassium</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Calcium</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Chloride</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First"> Ringer’s Injection, USP </p></td>
<td class="Botrule Lrule" align="center"><p class="First"> 500 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 8.6 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 0.33 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 0.3 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 309 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 5.5 <br>(5.0 to 7.5) </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 147.5 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First">4</p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 4.5 </p></td>
<td class="Botrule Lrule" align="center" rowspan="2"><p class="First"> 156 </p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" align="center"><p class="First">1000</p></td></tr>
</tbody>
</table>
<p>The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3a51376d-b25c-402a-b02e-15ff92abe2cf"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Ringer’s Injection, USP has value as a source of water and electrolytes. It is capable of inducing <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> depending on the clinical condition of the patient.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_96d88724-8990-469c-8294-00aa5fca0176"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ringer’s Injection, USP is indicated as a source of water and electrolytes.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_18b25151-7d4b-4019-a272-93624e2e8731"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Concomitant treatment with ceftriaxone and Ringer’s Injection, USP is contraindicated in newborns (≤28 days of age), even if separate infusion lines are used due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1c09efe6-5557-4aa5-ba2d-01d25fe8fedd"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Ringer’s Injection, USP should be used with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and in clinical states in which there exists <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>. </p>
<p>Ringer’s Injection, USP should be used with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and in conditions in which potassium retention is present. </p>
<p>Ringer’s Injection, USP should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation.</p>
<p>The intravenous administration of Ringer’s Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, congested states, or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> is directly proportional to the electrolyte concentrations of the injection. </p>
<p>In patients with diminished renal function, administration of Ringer’s Injection, USP may result in sodium or potassium retention.</p>
<p>In patients older than 28 days, including adults, ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Ringer’s Injection, USP, through the same infusion line (e.g., via a Y-connector). If the same infusion line is used for sequential administration, the line must be thoroughly <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> between infusions with a compatible fluid.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c10b6a03-bb89-4205-a063-dcbd596ca835"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Do not use plastic containers in series connections. Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. </p>
<p>Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> if the residual air in the container is not fully evacuated prior to administration.</p>
<p>Use of a vented intravenous administration set with the vent in the open position could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span>. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.</p>
<p>Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. </p>
<p>Caution must be exercised in the administration of Ringer’s Injection, USP to patients receiving corticosteroids or corticotropin.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_c48928e3-f280-4903-9954-915a3c685490"></a><a name="section-6.1"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_61cf6489-c72e-4897-84d0-826cb4e7c5ef"></a><a name="section-6.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_844cdbe4-75a3-4aa2-9490-95b81c207bb2"></a><a name="section-6.1.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with Ringer’s Injection, USP. It is also not known whether Ringer’s Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ringer’s Injection, USP should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a3444843-a902-48d3-9a3f-47472a4a033c"></a><a name="section-6.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The use of Ringer’s Injection, USP in pediatric patients is based on clinical practice.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a59a3e41-6e57-41e0-b309-6a03f7786280"></a><a name="section-6.3"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Ringer’s Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>Do not administer unless solution is clear and seal is intact.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_cd359544-e5a9-4d7c-9f1a-3a95e2d834e7"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions </h2>
<p class="First">For information on the use of Ringer’s Injection, USP with ceftriaxone, see <a href="#i4i_contraindications_id_18b25151-7d4b-4019-a272-93624e2e8731">CONTRAINDICATIONS</a> and <a href="#i4i_warnings_id_1c09efe6-5557-4aa5-ba2d-01d25fe8fedd">WARNINGS</a> sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_04d1f2d4-88aa-4117-9587-016d5aa34ae0"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reactions which may occur because of the solution or the technique of administration include febrile response, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> or <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> extending from the site of injection, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, and <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>. </p>
<p>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_ae09855b-3992-44d2-97f8-4522cbd9f40d"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<p>All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment. </p>
<p>Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a5f7c816-7fb1-4713-997e-a6f2a04ce004"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ringer’s Injection, USP in VIAFLEX plastic container is available as follows:</p>
<table width="100%">
<col width="23%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First"><span class="Bold">Code</span></p></td>
<td><p class="First"><span class="Bold">Size (mL)</span></p></td>
<td><p class="First"><span class="Bold">NDC</span></p></td>
</tr>
<tr>
<td><p class="First"> 2B2303 </p></td>
<td><p class="First"> 500 </p></td>
<td><p class="First"> 0338-0105-03 </p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First"> 2B2304 </p></td>
<td><p class="First"> 1000 </p></td>
<td><p class="First"> 0338-0105-04 </p></td>
</tr>
</tbody>
</table>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b452c57-3aeb-46a8-bec2-a403d0a485b4"></a><a name="section-10"></a><p></p>
<h1>DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2833d990-bc11-416e-9ec8-a6148eef4848"></a><a name="section-10.1"></a><p></p>
<h2>To Open</h2>
<p class="First">Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. If supplemental medication is desired, follow directions below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e8cd27d-8a26-4d3a-81f5-a6e40829c90e"></a><a name="section-10.2"></a><p></p>
<h2>Preparation for Administration</h2>
<dl>
<dt>1.</dt>
<dd>Suspend container from eyelet support. </dd>
<dt>2.</dt>
<dd>Remove protector from outlet port at bottom of container. </dd>
<dt>3.</dt>
<dd>Attach administration set. Refer to complete directions accompanying set. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5cf5e65e-cd9b-4a19-9bda-5abcaf927f0d"></a><a name="section-10.3"></a><p></p>
<h2>To Add Medication</h2>
<p class="First"><span class="Bold">WARNING:</span> Additives may be incompatible</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0cbdc939-58b5-45fa-9907-a2a2d31234fc"></a><a name="section-10.3.1"></a><p></p>
<h3>To add medication before solution administration</h3>
<dl>
<dt>1.</dt>
<dd>Prepare medication site. </dd>
<dt>2.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture medication port and inject. </dd>
<dt>3.</dt>
<dd>Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53dd9744-05b5-48c2-8baf-76ad53852d5e"></a><a name="section-10.3.2"></a><p></p>
<h3>To add medication during solution administration</h3>
<dl>
<dt>1.</dt>
<dd>Close clamp on the set. </dd>
<dt>2.</dt>
<dd>Prepare medication site. </dd>
<dt>3.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. </dd>
<dt>4.</dt>
<dd>Remove container from IV pole and/or turn to an upright position. </dd>
<dt>5.</dt>
<dd>Evacuate both ports by squeezing them while container is in the upright position. </dd>
<dt>6.</dt>
<dd>Mix solution and medication thoroughly. </dd>
<dt>7.</dt>
<dd>Return container to in use position and continue administration.</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a616f77e-efd1-4230-be6a-ae9fdadd4740"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation </span><br>Deerfield, IL 60015 USA</p>
<p>Printed in USA</p>
<p>07-19-73-751</p>
<p>Rev. October 2014 </p>
<p>Baxter, Pl 146 and Viaflex are trademarks of Baxter International Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5e3f6fa7-f2d5-471e-9631-2f676ada1419"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - PACKAGING LABELING</h1>
<div class="Figure">
<a name="id423"></a><img alt="Ringer's Representative container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76140511-686a-42c2-b3c1-32cfb71d24cb&amp;name=image-01.jpg">
</div>
<p class="First">2B2303<br>NDC 0338-0105-03</p>
<p>Ringer's<br>Injection USP</p>
<p>500 mL<br>EACH 100 mL CONTAINS 860 mg SODIUM CHLORIDE USP 33 mg<br>CALCIUM CHLORIDE USP 30 mg POTASSIUM CHLORIDE USP pH<br>5.5 (5.0 TO 7.5) pH MAY BE ADJUSTED WITH SODIUM HYDROXIDE<br>mEq/L SODIUM 147.5 POTASSIUM 4 CALCIUM 4.5 CHLORIDE<br>156 OSMOLARITY 309 mOsmol/L (CALC) STERILE<br>NONPYROGENIC SINGLE DOSE CONTAINER ADDITIVES MAY BE<br>INCOMPATIBLE CONSULT WITH PHARMACIST IF AVAILABLE WHEN<br>INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY<br>DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN<br>SEE DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG<br>WHICH MAINTAINS PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE FOUND<br>MUST NOT BE USED IN SERIES CONNECTIONS DO NOT ADMINISTER<br>SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS SOLUTION IS<br>CLEAR <span class="Bold">RX ONLY </span>STORE UNIT IN MOISTURE BARRIER OVERWRAP AT<br>ROOM TEMPERATURE (25ºC/77ºF) UNTIL READY TO USE AVOID<br>EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX CONTAINER<br>PL 146 PLASTIC</p>
<p>Baxter Logo<br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p>Made in USA</p>
<p>For Product Information<br>1-800-933-0303</p>
<p>Baxter VIAFLEX and<br>PL 146 are trademarks of <br>Baxter International Inc</p>
<div class="Figure">
<a name="id458"></a><img alt="Ringers Representative Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76140511-686a-42c2-b3c1-32cfb71d24cb&amp;name=image-02.jpg">
</div>
<p>2B2303Q</p>
<p>24-500 ML<br>VIAFLEX CONTAINER</p>
<p>RINGER'S INJECTION, USP</p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE<br>(17) YYMM00 (10) XXXXX</p>
<p>LOT<br>XXXXX</p>
<p>PRIMARY BAR CODE<br>(01) 50303380105033</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RINGERS 		
					</strong><br><span class="contentTableReg">sodium chloride, calcium chloride, potassium chloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0105</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION and CHLORIDE ION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">8.60 g  in 1000 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CALCIUM CHLORIDE</strong> (CALCIUM CATION and CHLORIDE ION) </td>
<td class="formItem">CALCIUM CHLORIDE</td>
<td class="formItem">0.33 g  in 1000 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION and CHLORIDE ION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">0.30 g  in 1000 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0105-04</td>
<td class="formItem">14  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1000 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-0105-03</td>
<td class="formItem">24  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016693</td>
<td class="formItem">03/22/1971</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">MANUFACTURE(0338-0105), ANALYSIS(0338-0105), PACK(0338-0105), LABEL(0338-0105), STERILIZE(0338-0105)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">194684502</td>
<td class="formItem">ANALYSIS(0338-0105)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c2d5806-0dd7-4d59-b4c3-87b052567d9d</div>
<div>Set id: 76140511-686a-42c2-b3c1-32cfb71d24cb</div>
<div>Version: 4</div>
<div>Effective Time: 20141014</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
